Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases

Journal of Clinical Immunology

Volumn 27, Issue 5, 2007, Pages 503-509

  Berger, Melvin ^a   Cunningham Rundles, Charlotte ^b   Bonilla, Francisco A ^c   Melamed, Isaac ^d   Bichler, Johann ^e   Zenker, Othmar ^e   Ballow, Mark ^f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d 1st Allergy and Clinical Research Center ^*  (United States)

^e CSL Behring AG   (Switzerland)

^f CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

Efficacy; IGIV >; Immunoglobulin; Liquid; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CARIMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADULT; AGAMMAGLOBULINEMIA; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34548201829     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-007-9096-9     Document Type: Article

References (30)

1. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU: Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94:S1-S63, 2005 (available at: http://www.jcaai.org/pp/pp-immunodeficiency-update_05-0602.pdf)
2. Chapel HM: Consensus on diagnosis and management of primary antibody deficiencies. Consensus panel for the diagnosis and management of primary antibody deficiencies. BMJ 308:581-585, 1994
3. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C: Primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology: Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(suppl 4):S525-553, 2006
4. Roifman CM, Levison H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1:1075-1077, 1987
5. Durandy A, Wahn V, Petteway S, Gelfand E: Immunoglobulin replacement therapy in primary antibody deficiency diseases-maximizing success. Int Arch Allergy Immunol 136:217-229, 2005
6. Gelfand EW: Differences between IGIV products: Impact on clinical outcome. Int Immunopharmacol 6:592-599, 2006
7. Epstein JS, Zoon KC: Important drug warning: Immune globulin intravenous (human) (IGIV) products. Neonatal Netw 19:60-62, 2000
8. Centers for Disease Control and Prevention (CDC): Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep 48:518-521, 1999
9. Pierce LR, Jain N: Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17:241-251, 2003
10. Borte M, Davies SV, Touraine J-L, Farber C-M, Lipsic T, Adams C, Spath P, Bolli R, Morell A, Andresen I: Clinical properties of a novel liquid intravenous immunoglobulin: Studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Transfus Med Hemother 31:126-134, 2004
11. Andresen I, Schmugge M, Ridolfi-Lüthi A, Adams C, Bender K: An open label, multi center study in pediatric acute idiopathic thrombocytopenic purpura. Presented at the European Hematology Association Annual Congress, Lyon, 2003. Abstract number 0763 (http://eurocongres.com/eha2003/eha_scientific.html)
12. FDA: Draft guidance for industry. Safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. http://www.fda.gov/ CBER/gdlns/igivimmuno.pdf
13. Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G: Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 3:1325-1333, 2003
14. Bjorkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ: Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 90:286-293, 2006
15. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, Wasserman RL, Pavlova BG, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich HJ: US-PID-IGIV 10%-Study Group 10: Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 26:388-395, 2006
16. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M: Subcutaneous IgG Study Group: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26:265-273, 2006
17. Cassidy EA, Pinciaro PJ, Berger M: For the Grifols 0404-OLEIG201 investigators: Antibody deficiency in the new millennium: Illnesses, absences, and concomitant medications-100 patient years' experience. J Allergy Clin Immunol 117:S110, 2006
18. Berger M, Pinciaro PJ: Flebogamma 5% investigators: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389-396, 2004
19. Eijkhout HW, Van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: Inter-University Working Party for the Study of Immune Deficiencies: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165-174, 2001
20. Nydegger UE, Sturzenegger M: Adverse effects of intravenous immunoglobulin therapy. Drug Safety 21:171-185, 1999
21. Ameratunga R, Sinclair J, Kolbe J: Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 136:111-113, 2004
22. Work Loss Data Institute: Official disability guidelines. 6/17/02. Available at: http://www.disabilitydurations.com/pr_repmdc.htm, 2002
23. Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG: Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32:1-10, 2004
24. Siegel J: Safety considerations in IGIV utilization. Int Immunopharmacol 6:523-527, 2006
25. Shah S: Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 62:S5-11, 2005
26. Orbach H, Katz U, Sherer Y, Shoenfeld Y: Intravenous immunoglobulin: Adverse effects and safe administration. Clin Rev Allergy Immunol 29:173-184, 2005
27. Berger M: Use of IGIV in Primary Immune Deficiency. Parts I and II. In UpToDate, Steihm ER, 2004. Updated, 2006
28. Kroez M, Kanzy EJ, Gronski P, Dickneite G: Hypotension with intravenous immunoglobulin therapy: Importance of pH and dimer formation. Biologicals 31:277-286, 2003
29. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, Tool AT, Koenderman AH, Kuijpers TW, Hack CE: Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95:1856-1861, 2000
30. Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Späth P, Schnorf J: Well-tolerated liquid intravenous immunoglobulin G preparations (IGIVs) have a low immunoglobulin G dimer content. J Autoimmunity 96(suppl):96 (abstract), 1999